Three OX40/OX40L biologics, three distinct binding modes in atopic dermatitis
Three OX40/OX40L biologics in atopic dermatitis trials — rocatinlimab, telazorlimab, amlitelimab — bind their targets in distinct ways, per new AlphaFold3 models in the Journal of Investigative Derma…